References

• Abell, C., Smith, A. and Blundell, T., (2020). Development of fragment-based approaches to build chemical tools for biology
• Aira, L. E., Villa, E., Colosetti, P., Gamas, P., Signetti, L., Obba, S., ... & Robert, G. (2018). The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim. Oncogene, 37(16), 2122-2136.
• Alves Avelar, L. A., Ruzic, D., Djokovic, N., Kurz, T., & Nikolic, K. (2020). Structure-based design of selective histone deacetylase 6 zinc binding groups. Journal of Biomolecular Structure and Dynamics, 38(11), 3166- 3177.
• Amr, A. E. G. E., Abo-Ghalia, M. H., Moustafa, G. O., Al-Omar, M. A., Nossier, E. S., & Elsayed, E. A. (2018). Design, synthesis, and docking studies of novel macrocyclic pentapeptides as anticancer multi-targeted kinase inhibitors. Molecules, 23(10), 2416
• Barelier, S., Pons, J., Marcillat, O., Lancelin, J. And Krimm, I., (2020). Fragment-Based Deconstruction of Bcl-Xl Inhibitors.doi.org/10.1021/jm100009z
• Benner, B., Good, L., Quiroga, D., Schultz, T. E., Kassem, M., Carson, W. E., ... & Wesolowski, R. (2020). Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. Drug Design, Development and Therapy, 14, 1693.
• Boudou-Rouquette, P., Tlemsani, C., Blanchet, B., Huillard, O., Jouinot, A., Arrondeau, J., ... & Goldwasser, F. (2016). Clinical pharmacology, drug-drug interactions, and safety of pazopanib: a review. Expert Opinion on Drug Metabolism & Toxicology, 12(12), 1433-1444.
• Carles, F., Bourg, S., Meyer, C., & Bonnet, P. (2018). PKIDB: A curated, annotated, and updated database of protein kinase inhibitors in clinical trials. Molecules, 23(4), 908
• Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q. And Zhou, J., (2020). Fragment-Based Drug Design and Identification of HJC0123, A Novel Orally Bioavailable STAT3 Inhibitor for Cancer Therapy
• Chen, H., Zhou, X., Wang, A., Zheng, Y., Gao, Y. And Zhou, J., (2020). Evolutions in Fragment- Based Drug Design: The Deconstruction- Reconstruction Approach.
• Ciulli, A. And Abell, C., (2020). Fragment-Based Approaches to Enzyme Inhibition.
• D'Angelo, A., Bagby, S., Galli, I. C., Bortoletti, C., & Roviello, G. (2020). Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. Expert Review of Clinical Pharmacology, 1-8.
• Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017). Drugging the'undruggable'cancer targets. Nature Reviews Cancer, 17(8), 502
• Debnath, S., Kanakaraju, M., Islam, M., Yeeravalli, R., Sen, D., & Das, A. (2019). In silico design, synthesis, and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents. Computational Biology and Chemistry, 83, 107156.
• Doi, T., Kurokawa, Y., Sawaki, A., Komatsu, Y., Ozaka, M., Takahashi, T., ... & Nishida, T. (2019). Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. European Journal of Cancer, 121, 29-39.
• Eguida, M., & Rognan, D. (2020). A computer vision approach to align and compare protein cavities: Application to fragment-based drug design. Journal of Medicinal Chemistry.
• Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016). Twenty years on: the impact of fragments on drug discovery. Nature reviews Drug discovery, 15(9), 605.
• Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016). Epigenetic modulators, modifiers, and mediators in cancer aetiology and progression. Nature Reviews Genetics, 17(5), 284-299.
• Feng, W., Zhang, M., Wu, Z. X., Wang, J. Q., Dong, X. D., Yang, Y., ... & Yang, D. H. (2020). Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells. Frontiers in Oncology, 10.
• Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y. And Liu, D., (2020). STAT Inhibitors for Cancer Therapy
• Garner, P., Cox, P. B., Rathnayake, U., Holloran, N., & Erdman, P. (2019). Design and Synthesis of Pyrrolidine-based Fragments That Sample Three-dimensional Molecular Space. ACS Medicinal Chemistry Letters, 10(5), 811- 815.
• Gu, Y., Mohammad, I. And Liu, Z., (2020). Overview of the STAT-3 Signalling Pathway in Cancer and The Development of Specific Inhibitors (Review)
• Hassaan, E., Hohn, C., Ehrmann, F. R., Goetzke, F. W., Movsisyan, L., Hüfner-Wulsdorf, T., ... & Klebe, G. (2020). Fragment Screening Hit Draws Attention to a Novel Transient Pocket Adjacent to the Recognition Site of the tRNA-Modifying Enzyme TGT. Journal of Medicinal Chemistry.
• Howard, N., Abell, C., Blackmore, W., Chessari, G., Congreve, M., Howard, S., Jhoti, H., W. Murray, C., Seavers, L. And Montfort, R., (2020). Application of Fragment Screening and Fragment Linking to The Discovery of Novel Thrombin Inhibitors,
• Jacquemard, C., and Kellenberger, E., (2019). A bright future for fragment-based drug discovery: what does it hold? Exp. Opin. Drug Discov. 14, 413-416. doi: 10.1080/17460441.2019.1583643
• Kang, C. B. (2019) F-NMR in target-based drug discovery. Curr. Med. Chem. 26, 4964- 4983. doi: 10.2174/0929867326666190610160534.
• Kidd, S. L., Osberger, T. J., Mateu, N., Sore, H. F., & Spring, D. R. (2018). Recent applications of diversity-oriented synthesis toward novel, 3-dimensional fragment collections. Frontiers in chemistry, 6, 460.
• Kirsch, P., Hartman, A. M., Hirsch, A. K., & Empting, M. (2019). Concepts and core principles of fragment-based drug design. Molecules, 24(23), 4309.
• Kleandrova, V. V., & Speck-Planche, A. (2020). The QSAR paradigm in fragment-based drug discovery: from the virtual generation of target inhibitors to multi-scale modeling. Mini reviews in medicinal chemistry, 20(14), 1357-1374.
• Li Q (2020) Application of Fragment-Based Drug Discovery to Versatile Targets. Front. Mol. Biosci. 7:180. doi: 10.3389/fmolb.2020.00180
• Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., ... & Joshi, M. (2019). Erdafitinib in locally advanced or metastatic urothelial carcinoma. New England Journal of Medicine, 381(4), 338- 348
• Murray, C. W., & Rees, D. C. (2016). Opportunity knocks: organic chemistry for fragment- based drug discovery (FBDD). Angewandte Chemie International Edition, 55(2), 488- 492.
• Murray, C. W., Newell, D. R., & Angibaud, P. (2019). A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA. MedChemComm, 10(9), 1509-1511.
• Obata, Y., Horikawa, K., Shiina, I., Takahashi, T., Murata, T., Tasaki, Y., ... & Abe, R. (2018). Oncogenic Kit signalling on the Golgi is suppressed by blocking secretory trafficking with M-COPA in gastrointestinal stromal tumours. Cancer Letters, 415, 1- 10.
• Obata, Y., Horikawa, K., Takahashi, T., Akieda, Y., Tsujimoto, M., Fletcher, J. A., ... & Abe, R. (2017). Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. Oncogene, 36(26), 3661-3672.
• Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., ... & Wong, S. (2016). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374(4), 311-322.
• Rochlani, S. P., Choudhari, P. B., & Dahiwade, L. K. (2020). Phytochemical and Pharmacophoric Fragment Based Anticancer Drug Development. Current computer-aided drug design
• Saito, Y., Takahashi, T., Obata, Y., Nishida, T., Ohkubo, S., Nakagawa, F., ... & Sugase, T. (2020). TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours. British journal of cancer, 122(5), 658-667.
• Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., ... & Jaeger, U. (2018). Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New England Journal of Medicine, 378(12), 1107-1120
• Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: a cancer journal for clinicians, 70(1), 7-30.
• Wong, A., Hirpara, J., Pervaiz, S., Eu, J., Sethi, G. And Goh, B., (2020). Do STAT3 Inhibitors Have Potential in the Future for Cancer Therapy?
• Singh, M., Tam, B., & Akabayov, B. (2018). NMR- fragment based virtual screening: A brief overview. Molecules, 23(2), 233.
• Xi, T., Qingli, T., Fengrui, L., & Fengxiang, T. (2018). Advances in the Synthesis of Venetoclax as a New Drug for the Treatment of Chronic Lymphocytic Leukemia. Chemistry, (2), 3.
• Tap, W. D., Gelderblom, H., Palmerini, E., Desai, J., Bauer, S., Blay, J. Y., ... & Thomas, D. M. (2019). Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. The Lancet, 394(10197), 478-487.
• Yu, W., Xiao, H., Lin, J. And Li, C., 2020. Discovery of Novel STAT3 Small Molecule Inhibitors Via In Silico Site-Directed Fragment-Based Drug Design.J Med Chem.
• Temple, K. J., Engers, J. L., Long, M. F., Gregro, A. R., Watson, K. J., Chang, S., ... & Bridges, T. M. (2019). Discovery of a novel 3, 4- dimethylcinnoline carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic & medicinal chemistry letters, 29(21), 126678
• Yue, P. And Turkson, J., 2020. Targeting STAT3 In Cancer: How Successful Are We?
• Torres-Collado, A. X., Knott, J., & Jazirehi, A. R. (2018). Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAFV600E-Specific Inhibitor). Cancers, 10(6), 157
• Zhang, W., Heinzmann, D., & Grippo, J. F. (2017). Clinical pharmacokinetics of vemurafenib. Clinical Pharmacokinetics, 56(9), 1033- 1043.
• Zhong, W., Koay, A., Ngo, A., Li, Y., Nah, Q., Wong, Y. H., ... & Foo, K. (2019). Targeting the bacterial epitranscriptome for antibiotic development: Discovery of novel tRNA- (N1G37) methyltransferase (TrmD) inhibitors. ACS infectious diseases, 5(3), 326-335.
• Wesolowski, R., Sharma, N., Reebel, L., Rodal, M. B., Peck, A., West, B. L., ... & Le, M. H. (2019). Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Therapeutic advances in medical oncology, 11, 1758835919854238.